What have we learned from cancer immunotherapy in the last 3 years?

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Ascierto, Paolo A ^a   Marincola, Francesco M ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

Efficacy; Immunotherapy; Melanoma; Sequencing; Survival

Indexed keywords

DABRAFENIB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PLACEBO; TALIMOGENE LAHERPAREPVEC; TICILIMUMAB; VEMURAFENIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTATIC MELANOMA; NONHODGKIN LYMPHOMA; NOTE; SOLID TUMOR; UVEA MELANOMA; WORLD HEALTH ORGANIZATION; IMMUNOTHERAPY; NEOPLASMS;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84901634151     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-141     Document Type: Note

References (89)

1. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy - revisited. Nat Rev Drug Discov 2011, 10:591-600. 10.1038/nrd3500, 21804596.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723. 10.1056/NEJMoa1003466, 3549297, 20525992.
3. Yervoy (ipilimumab) EU summary of product characteristics, Dec 2013. [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf].
4. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006, 18:206-213. 10.1016/j.coi.2006.01.011, 16464564.
5. Chen L, Files DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature Rev Immunol 2013, 13:227-242.
6. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009, 206:1717-1725. 10.1084/jem.20082492, 2722174, 19581407.
7. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008, 13:2-9. 10.1634/theoncologist.13-S4-2, 19001145.
8. Blank CU. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr Opin Oncol 2014, 26(2):204-214. 10.1097/CCO.0000000000000054, 24424272.
9. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:481-489.
10. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 22:252-264.
11. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate antitumor immunity. Curr Opin Immunol 2012, 24:207-212. 10.1016/j.coi.2011.12.009, 3319479, 22236695.
12. ClinicalTrials.gov: a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world Clinicaltrials.gov, accessed March 2014.
13. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014, 257(1):107-126. 10.1111/imr.12131, 24329793.
14. Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012, 18(2):160-175. 10.1097/PPO.0b013e31824d4465, 3315690, 22453018.
15. Lu YC, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA, Robbins PF. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol 2013, 190(12):6034-6042. 10.4049/jimmunol.1202830, 23690473.
16. Ledford H. Cancer treatment: the killer within. Nature 2014, 508(7494):24-26. 10.1038/508024a, 24695297.
17. Weiss SA, Chandra S, Pavlick AC. Update on vaccines for high-risk melanoma. Curr Treat Options Oncol 2014, Epub ahead of print.
18. Galluzzi L, Lugli E. Cancer immunotherapy turns viral. OncoImmunology 2013, 2:e24801-e24802.
19. Andtbacka RHI, Collichio FA, Amatruda T, Senzer NN, Chesney J, Delman KA, Spitler LE, Puzanov I, Doleman S, Ye Y, Vanderwalde AM, Coffin R, Kaufman H. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma [abstract]. J Clin Oncol 2013, 31(suppl). LBA9008.
20. Kaufman H, Andtbacka RHI, Harrington K, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Vanderwalde AM, Coffin R. Secondary endpoints from OPTiM: A multicenter, randomized phase 3 trial of talimogene laherparepvec vs GM-CSF for the treatment of unresected stage IIIB/C and IV melanoma [abstract]. Eur J Cancer 2013, 49(suppl 2):3733.
21. Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD, Knutson KL. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res 2014, Epub ahead of print.
22. Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013, 25:261-267. 10.1016/j.coi.2013.03.004, 23579076.
23. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420. 10.1158/1078-0432.CCR-09-1624, 19934295.
24. Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy?. Clin Cancer Res 2009, 15:7116-7118. 10.1158/1078-0432.CCR-09-2376, 19934296.
25. Topalian SL, Sznol M, Brahmer JR, McDermott DF, Smith DC, Gettinger SN, Taube JN, Drake CG, Pardoll DM, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Antonia SJ, Spigel DR, Lawrence DP, Kollia G, Gupta AK, Wigginton JM, Hodi FS. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial [abstract]. J Clin Oncol 2013, 31(suppl):3002.
26. Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK, Kirkwood JM. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 2012, 18:336-341. 10.1158/1078-0432.CCR-11-2323, 3422891, 22142824.
27. Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, Biagioli M, Altomonte M, Maio M. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 2013, 62:1021-1028. 10.1007/s00262-013-1418-6, 23591982.
28. Maio M, Bondarenko I, Robert C, Thomas L, Garbe C, Testori A, Lu H, Chin K, Wolchok JD. Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma [abstract]. Eur J Cancer 2013, 49(suppl 2):3704.
29. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012, 18(7):2039-2047. 10.1158/1078-0432.CCR-11-1823, 3319861, 22271879.
30. Robert C, Thomas L, Bondarenko I, O'Day S, JW MD, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526. 10.1056/NEJMoa1104621, 21639810.
31. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebbé C. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013, 24:2174-2180. 10.1093/annonc/mdt161, 23666915.
32. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, . for the CA184-043 Investigators Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014, 15:700-712. for the CA184-043 Investigators.
33. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma [abstract]. Eur J Cancer 2013, 49(suppl 2):24LBA.
34. Hodi FS, Topalian SL, Brahmer JR, McDermott DF, Smith DC, Gettinger S, Taube JM, Pardoll DM, Wigginton JM, Sznol M. Survival and long-term safety in patients (pts) with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract]. Eur J Cancer 2013, 49(suppl 2):880.
35. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, Epub ahead of print.
36. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144. 10.1056/NEJMoa1305133, 23724846.
37. Brignone C, Escudier B, Grygar C, Marcu M, Triebel F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 2009, 15:6225-6231. 10.1158/1078-0432.CCR-09-0068, 19755389.
38. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012, 30:2046-2054. 10.1200/JCO.2011.38.4032, 22547592.
39. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013, 24:75-83. 10.1093/annonc/mds213, 22858559.
40. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013, 24:1813-1821. 10.1093/annonc/mdt107, 23535954.
41. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:509-517. 10.1016/S1470-2045(12)70007-4, 22326922.
42. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366(26):2455-2465. 10.1056/NEJMoa1200694, 3563263, 22658128.
43. Carnahan J, Beltran PJ, Babij C, Le Q, Rose MJ, Vonderfecht S, Kim JL, Smith AL, Nagapudi K, Broome MA, Fernando M, Kha H, Belmontes B, Radinsky R, Kendall R, Burgess TL. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther 2010, 9:2399-2410. 10.1158/1535-7163.MCT-10-0181, 20663930.
44. Tafinlar (dabrafenib) EU summary of product characteristics, 2013. [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002604/WC500149671.pdf].
45. Zelboraf (vemurafenib) EU summary of product characteristics, 2014. [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002409/WC500124317.pdf].
46. Mangana J, Goldinger SM, Schindler K, Rozati S, Frauchiger AL, Rechsteiner M, Moch H, Romano E, Kaehler KC, Michielin O, Hauschild A, Hoeller C, Dummer R. Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: association with overall survival? [abstract]. J Clin Oncol 2013, 31(suppl):9025.
47. Ascierto PA, Simeone E, Chiarion Sileni V, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, Cognetti F, Testori A, Bernengo MG, Guida M, Marconcini R, Mandalà M, Cimminiello C, Rinaldi G, Aglietta M, Queirolo P. Clinical experience with ipilimumab 3 mg/kg: Real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014, in press.
48. Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L, Marchetti P, de Rosa F, Nuzzo C, Testori A, Cocorocchio E, Bernengo MG, Guida M, Marconcini R, Merelli B, Parmiani G, Rinaldi G, Aglietta M, Grosso M, Queirolo P. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the Expanded Access Programme. J Exp Clin Cancer Res 2014, 33:30. 10.1186/1756-9966-33-30, 3996509, 24708900.
49. Lopez Martin JA, Gonzalez Cao M, Sereno M, Mayordomo J, Hidalgo M, Campos B, Cumplido D, Zambrana F, Medina J, Berrocal A. Ipilimumab in older patients: Spanish melanoma multidisciplinary group (GEM) experience in the expanded access programme [abstract]. Ann Oncol 2012, 23(suppl 9):3233.
50. Lawrence D, McDermott D, Hamid O, Weber J, Wolchok J, Richards J, Minor D, Pavlick A, Sznol M, Hwu P, Urba W, Amin A, Bennett K, Michener T, Balogh A, Hodi FS. Treatment of Patients (pts) With Stage III or IV Melanoma on an Ipilimumab (Ipi) Expanded Access Program (EAP): Results for 3 mg/kg Cohort 2012, Hollywood, USA: Presented at Society for Melanoma Research (SMR) Congress.
51. Lawrence D, McDermott D, Hamid O, Weber J, Wolchok J, Richards J, Amin A, Bennett K, Balogh A, Hodi FS. Ipilimumab (IPI) Expanded Access Program (EAP) for patients (pts) with Stage III/IV melanoma: safety data by subgroups [abstract]. Ann Oncol 2012, 23(suppl 9):1129P.
52. Chandra S, Madden KM, Kannan R, Pavlick AC. Evaluating the safety of anti-CTLA-4 therapy in elderly patients with unresectable melanoma [abstract]. J Clin Oncol 2013, 31(suppl):9063.
53. Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, Marchetti P, De Galitiis F, Mandalà M, Guida M, Simeone E, Ascierto PA. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol 2013, 24:2911-2915. 10.1093/annonc/mdt376, 24067719.
54. Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabrò L, Rossi CD, Giacomo AM, Ferrucci PF, Ridolfi L, Altomonte M, Miracco C, Balestrazzi A, Maio M. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother 2012, 61:41-48. 10.1007/s00262-011-1089-0, 21833591.
55. Khattak MA, Fisher R, Hughes P, Gore M, Larkin J. Ipilimumab activity in advanced uveal melanoma. Melanoma Res 2013, 23:79-81. 10.1097/CMR.0b013e32835b554f, 23211837.
56. Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber cancer institute, Massachusetts general hospital, memorial Sloan-Kettering cancer center, and university hospital of Lausanne experience. Cancer 2013, 119:3687-3695. 3986037, 23913718.
57. Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, Ferrucci PF, Marchetti P, De Galitiis F, Queirolo P, Tornari E, Marconcini R, Calabrò L, Maio M. Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 2014, 50:121-127. 10.1016/j.ejca.2013.09.007, 24100024.
58. Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD. Ipilimumab for patients with advanced mucosal melanoma. Oncologist 2013, 18:726-732. 10.1634/theoncologist.2012-0464, 23716015.
59. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012, 13:459-465. 10.1016/S1470-2045(12)70090-6, 22456429.
60. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012, 13:879-886. 10.1016/S1470-2045(12)70324-8, 22894884.
61. Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Giannarelli D, Parmiani G, Maio M. The Italian Network for Tumor Biotherapy (NIBIT)-M1 study: 2-years survival update for metastatic melanoma patients treated with ipilimumab in combination with fotemustine [abstract]. Eur J Cancer 2013, 49(suppl 2):3740.
62. Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L, Maio M, Di Giacomo AM, Antonuzzo A, Cognetti F, Ferraresi V, Ridolfi L, Guidoboni M, Guida M, Pigozzo J, Chiarion Sileni V. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 2014, 118:109-116. 10.1007/s11060-014-1400-y, 4023079, 24532241.
63. Shahabi V, Whitney G, Hamid O, Schmidt H, Chasalow SD, Alaparthy S, Jackson JR. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother 2012, 61:733-737. 10.1007/s00262-012-1227-3, 22382362.
64. Edwards RH, Ward MR, Wu H. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet 2004, 41:270-272. 10.1136/jmg.2003.016667, 1735752, 15060100.
65. Lebbé C, McDermott DF, Robert C, Lorigan P, Ottensmeier CH, Wolchok J, Garbe C, Messina M, Hoos A, Weber JS. Ipilimumab improves survival in previously treated advanced melanoma patients with poor prognostic factors: subgroup analysis from a phase III trial [abstract]. Ann Oncol 2010, 21(suppl 8):13240.
66. Gettinger SN, Horn L, Antonia SJ, Spigel DR, Gandhi L, Sequist LV, Sankar V, Ahlers CM, Wigginton JM, Kollia G, Gupta A, Brahmer JR. Efficacy of nivolumab (anti-PD-1; BMS-936558; ono-4538) in patients with previously treated advanced non-small cell lung cancer (NSCLC): subpopulation response analysis in a phase 1 trial [abstract]. J Thorac Oncol 2013, 8(suppl 2):2.11-038.
67. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 2012, 10:107. 10.1186/1479-5876-10-107, 3464706, 22640478.
68. Ackerman A, McDermott DF, Lawrence DP, Gunturi A, Flaherty KT, Giobbie-Hurder A, Hodi FS, Ibrahim N, Atkins MB, Cho DC, Sullivan RJ. Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib [abstract]. J Clin Oncol 2012, 30(suppl):8569.
69. Ascierto PA, Simeone E, Grimaldi AM, Curvietto M, Esposito A, Palmieri G, Mozzillo N. Do BRAF inhibitors select for populations with different disease progression kinetics?. J Transl Med 2013, 11:61. 10.1186/1479-5876-11-61, 3599508, 23497384.
70. Ascierto PA, Simeone E, Chiarion Sileni V, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, Testori A, Queirolo P, Bernengo MG, Guida M, Galli L, Mandalà M, Cimminiello C, Rinaldi G, Carnevale-Schianca F, Maio M. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access programme. Cancer Invest 2014, 32:144-149. 10.3109/07357907.2014.885984, 24484235.
71. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncol 2013, 14:e60-e69. 10.1016/S1470-2045(12)70539-9, 23369684.
72. Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, Esposito A, Paone M, Palla M, Palmieri G, Caracò C, Ciliberto G, Mozzillo N, Ascierto PA. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunol 2014, in press.
73. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931. 10.1056/NEJMoa1112824, 3345206, 22397654.
74. Stamell E, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Rad Onc Biol Phys 2013, 85:293-295.
75. Hodge JW, Ardiani A, Farsaci, Kwilas AR, Gameiro SR. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol 2012, 39:323-339. 10.1053/j.seminoncol.2012.02.006, 3356994, 22595055.
76. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013, 19:393-403. 10.1158/1078-0432.CCR-12-1626, 23204132.
77. Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 2012, 209:201-209. 10.1084/jem.20112275, 3280881, 22330682.
78. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010, 107:4275-4280. 10.1073/pnas.0915174107, 2840093, 20160101.
79. Selby M, Engelhardt J, Lu LS, Quigley M, Wang C, Chen B, Korman AJ. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models [abstract]. J Clin Oncol 2013, 31(suppl):3061.
80. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133. 10.1056/NEJMoa1302369, 23724867.
81. Wolchok JD, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, Rizvi NA, Lesokhin AM, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba B, Feely W, Hong Q, Horak CE, Korman AJ, Wigginton JM, Gupta AK, Sznol M. Clinical activity and safety of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients with advanced melanoma [abstract]. J Clin Oncol 2013, 31(suppl):9021.
82. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72:917-927. 10.1158/0008-5472.CAN-11-1620, 3288154, 22186141.
83. Hodi FS, Lee SJ, McDermott DF, Rao UNM, Butterfield LH, Tarhini AA, Leming PD, Puzanov I, Kirkwood JM. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608 [abstract]. J Clin Oncol 2013, 31(suppl). CRA9007.
84. Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, et al. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011, 17:3064-3076. 10.1158/1078-0432.CCR-10-2234, 3096674, 21558394.
85. Callahan MK, Horak CE, Curran MA, Hollman T, Schaer DA, Yuan J, Lesokhin AM, Kitano S, Hong Q, Ariyan CE, Busam KJ, Feely W, Jure-Kunkel M, Grosso J, Simon JS, Korman AJ, Wigginton JM, Gupta AK, Sznol M, Wolchok JD. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab [abstract]. J Clin Oncol 2013, 31(suppl):3003.
86. Grosso JF, Horak CE, Inzunza D, Cardona DM, Simon JS, Gupta AK, Sankar V, Park JS, Kollia G, Taube JM, Anders R, Jure-Kunkel M, Novotny J, Taylor CR, Zhang X, Phillips T, Simmons P, Cogswell J. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract]. J Clin Oncol 2013, 31(suppl):3016.
87. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E, Robert C. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 2013, 24:1697-1703. 10.1093/annonc/mdt027, 23439861.
88. Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 2014, Apr 3. [Epub ahead of print].
89. Wilgenhof S, Du Four S, Vandenbroucke F, Everaert H, Salmon I, Liénard D, Marmol VD, Neyns B. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 2013, 36:215-222. 10.1097/CJI.0b013e31828eed39, 23502769.